Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) closed the day trading at $2.10 down -8.30% from the previous closing price of $2.29. On the day, 2821953 shares were traded.
Ratios:
For a better understanding of AMLX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.38 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.33. For the most recent quarter (mrq), Quick Ratio is recorded 5.20 and its Current Ratio is at 5.66. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on March 18, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $32 previously.
On March 11, 2024, Robert W. Baird Downgraded its rating to Neutral which previously was Outperform and also lowered its target price recommendation from $37 to $4.
Leerink Partners Downgraded its Outperform to Market Perform on March 11, 2024, whereas the target price for the stock was revised from $27 to $4.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 05 ’24 when Klee Justin B. sold 4,135 shares for $18.73 per share. The transaction valued at 77,440 led to the insider holds 2,959,308 shares of the business.
Cohen Joshua B sold 4,135 shares of AMLX for $77,440 on Mar 05 ’24. The Co-Chief Executive Officer now owns 3,023,002 shares after completing the transaction at $18.73 per share. On Mar 05 ’24, another insider, FRATES JAMES M, who serves as the Chief Financial Officer of the company, sold 1,792 shares for $18.73 each. As a result, the insider received 33,560 and left with 134,784 shares of the company.
Valuation Measures:
As of this moment, Amylyx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 2.98. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.37 while its Price-to-Book (P/B) ratio in mrq is 0.33.
Stock Price History:
Over the past 52 weeks, AMLX has reached a high of $31.77, while it has fallen to a 52-week low of $2.25.
Shares Statistics:
A total of 67.71M shares are outstanding, with a floating share count of 47.57M. Insiders hold about 29.83% of the company’s shares, while institutions hold 89.44% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from AMLX analysts. The consensus estimate for the next quarter is $4.29, with high estimates of $2.10 and low estimates of $18.05.
Analysts are recommending an EPS of between $Healthcare and $Communication Services for the fiscal current year, implying an average EPS of $Energy.
